Erratum in: Cost per responder for upadacitinib vs abatacept in patients with moderate-to-severe Rheumatoid Arthritis in Italy

Authors

  • Roberto Caporali Department of Clinical and Community Science (DISCCO), University of Milan and Department of Rheumatology and Medical Science, ASST Pini-COT, Milan - Italy
  • Roberto Ravasio Department of Health Economics, Pharmes Srl, Milan, Italy
  • Paola Raimondo Market Access Provider, Milan - Italy
  • Fausto Salaffi Rheumatology Clinic, “Carlo Urbani” Hospital, Department of Clinical and Molecular Science, Università Politecnica delle Marche, Jesi (AN) - Italy

DOI:

https://doi.org/10.33393/grhta.2022.2383

Abstract

In the article “Cost per responder for upadacitinib vs abatacept in patients with moderate-to-severe Rheumatoid Arthritis in Italy”, (1) which appeared in Volume 8, Issue 1 of  Global & Regional Health Technology Assessment, the values appearing in Fig. 5 C and D, inadvertently repeated the values reported in Fig. 5 A and B. Affected data have been corrected in the article now appearing online. The authors apologize for any inconvenience caused to the readers by these changes, which do not affect the final results of the study.

The final version of this article is available online and includes a reference to this correction.

References

Caporali R, Ravasio R, Raimondo P, Salaffi F. Cost per responder for upadacitinib vs abatacept in patients with moderate-to-severe Rheumatoid Arthritis in Italy. Glob Region Health Technol Assess. 2021;8:69-79. https://doi.org/10.33323/grhta.2021.2267 DOI: https://doi.org/10.33393/grhta.2021.2267

Published

2022-02-17

How to Cite

1.
Caporali R, Ravasio R, Raimondo P, Salaffi F. Erratum in: Cost per responder for upadacitinib vs abatacept in patients with moderate-to-severe Rheumatoid Arthritis in Italy. Grhta [Internet]. 2022 Feb. 17 [cited 2022 Jul. 1];9(1):30. Available from: https://journals.aboutscience.eu/index.php/grhta/article/view/2383

Issue

Section

Erratum